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Genotype-dependent associations between
serotonin transporter gene (SLC6A4) DNA
methylation and late-life depression
Dilys Lam1, Marie-Laure Ancelin3, Karen Ritchie3,4, Rosanne Freak-Poli5, Richard Saffery1,2 and Joanne Ryan1,2,3,5*
Abstract
Background: Disrupted serotonergic signaling is often a feature of depression and the role of the serotonin
transporter gene (SLC6A4), responsible for serotonin re-uptake, has received much attention in this regard. Most
studies have focused on the polymorphic 5-HTTLPR upstream repeat, or DNA methylation at the promoter CpG
island. Few studies have explored the influence of genetic variation across the gene on DNA methylation, and their
combined association with depression risk. The aim of this study was to determine whether genetic variation in the
SLC6A4 gene influences promoter DNA methylation, and whether these are associated with depression status.
Method: The ESPRIT study involves a community-based population of older individuals (> 65 years of age). Major
depressive disorder (MDD) was diagnosed according to DSM-IV (American Psychiatric Association, 1994) criteria, and
severe depressive symptoms assessed by the Centre for Epidemiological Studies Depression (CES-D) Scale.
Sequenom MassARRAY was used to measure SLC6A4 methylation status (n = 302).
Results: Nominally significant associations were observed between SLC6A4 genetic variants (5-HTTLPR, rs140700,
rs4251417, rs6354, rs25528, rs25531) and DNA methylation at several CpG sites. In multivariate regression, DNA
methylation was associated with depression status, but only in the presence of specific genotypes. In individuals
homozygous for the short 5-HTTLPR and 5-HTTLPR/r25531 alleles, lower methylation at two CpGs was associated
with depression (β = − 0.44 to β = − 0.31; p = 0.001 to p = 0.038).
Conclusion: We present evidence for genotype-dependent associations between SLC6A4 methylation and depression.
Genetic variants may also play a role in influencing promoter methylation levels and its association with depression.
Keywords: Depression, DNA methylation, Epigenetics, Genetic variation, Serotonin transporter
Background
Serotonin deficiency was one of the earliest hypothesis of
depression causality [1, 2]. This came from the discovery
of a class of antidepressants, the selective serotonin
re-uptake inhibitors (SSRIs), which block the reuptake of
the neurotransmitter and therefore increasing its availabil-
ity. SSRIs are thus commonly prescribed to treat depres-
sion, however the response rate remains relatively modest
(around 50%) [3]. The serotonin transporter (5-HTT),
encoded by the serotonin transporter gene (SLC6A4), is a
principle regulator of serotonergic neurotransmission and
the active target of SSRIs [4]. Thus, the role of SLC6A4
and its (dys)regulation has been a major focus of depres-
sion research.
One feature of SLC6A4 which has been the subject of
much research, is the upstream gene-linked polymorphic
region, 5-HTTLPR. A 44 bp insertion/deletion variable
number tandem repeat (VNTR), results in either short (S)
or long (L) alleles. The S allele results in lower SLC6A4
transcriptional levels and therefore reduced reuptake of
serotonin [5, 6]. There is some evidence that 5-HTTLPR
genotype affects vulnerability to a broad range of behav-
ioural disorders including depression [1]. However, these
associations have not been consistently found [7], suggest-
ing that other regulatory mechanisms and factors are
likely to contribute to depression risk [8–10].
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Approximately 1 kb downstream from 5-HTTLPR
lies another widely studied regulatory element, a CpG
island that spans the upstream promoter of exon 1
and the transcriptional start site [11]. DNA methyla-
tion of this compact region of CpG sites has been as-
sociated with reduced expression [11]. Previous,
generally small studies have investigated the associ-
ation between depression and SLC6A4 DNA methyla-
tion in peripheral tissues, but with conflicting
findings [12–20]. It is now clear that genetic variation
is an important regulator of DNA methylation across
the genome [21], yet only a few studies have exam-
ined whether 5-HTTLPR influences methylation and/
or the association between methylation and depres-
sion [15, 16]. To date the effects of other SLC6A4
genetic variants on DNA methylation and on the po-
tential link between depression and methylation, have
yet to be investigated.
Using data gathered as part of a large general popula-
tion cohort study of older persons, this study firstly in-
vestigated whether SLC6A4 genetic variation across the
gene influences promoter DNA methylation and sec-
ondly, whether depression is associated with DNA
methylation independently and/or in combination with
genetic variation.
Methods
The ESPRIT study
Participants included in this study were part of the
French ESPRIT study of neuropsychiatric disorders in
an older population [22]. Eligible participants aged
65 years and older from the non-institutionalised gen-
eral population were randomly recruited from elect-
oral rolls within the Montpellier district. Recruited
participants to ESPRIT provided written informed
consent and were asked to undergo standardized
health and psychiatric interviews, as well as extensive
clinical assessments. Information was collected on the
participants’ lifestyle, health and medical use. The
study protocol was approved by the Ethical Commit-
tee of University Hospital of Kremlin-Bicêtre, France.
Depression measures
Major depressive disorder (MDD) was diagnosed ac-
cording to the Diagnostic and Statistical Manual of
Mental Disorders-IV (DSM-IV) (American Psychiatric
Association, 1994) criteria, using the Mini International
Neuropsychiatric Interview (MINI, French version 5.00)
[23]. Diagnoses were further reviewed and validated by
a panel of psychiatrists and a psychologist with access
to information from participants’ health assessments.
Severity of depressive symptoms was assessed by the
Centre for Epidemiological Studies-Depression (CES-D)
scale, a self-reporting questionnaire previously validated
within the older population [24, 25]. A score of 16 or
above is considered the threshold of depressive symp-
toms warranting further clinical investigation [25].
Thus, late-life depression was defined in this study as
having a diagnosis of MDD or high levels of depressive
symptoms (CES-D ≥ 16).
Genotyping
Blood samples were collected at recruitment following
clinical assessment. In concordance with previous SLC6A4
methylation association studies in blood [12–15, 17, 19,
20], genomic DNA was extracted from white blood cells
using a standard procedure [26] and used for genotyping
and methylation analysis. Along with 5-HTTLPR, five sin-
gle nucleotide polymorphisms (SNPs) (rs140700, rs25528,
rs4251417, rs6354, rs25531) spanning the SLC6A4 gene
were also genotyped. These were chosen on the basis of
allele frequencies and prior associations with depression
[3, 26, 27]. Genotyping of 5-HTTLPR was performed as
previously described [26], and SNPs were genotyped by
KBiosciences (UK), using the KBioscience Competitive
Allele-Specific PCR SNP genotyping system (KASPar)
[28]. 5-HTTLPR can also be considered in combination
with rs25531, a SNP that lies within the repeat region and
has been reported to modify transcriptional activity of
5-HTTLPR [27, 29]. 5-HTTLPR/rs25531 describes the
triallelic polymorphism accounting for both 5-HTTLPR
and rs25531 genotypes. χ2-tests were used to calculate
whether the distribution of genotype frequencies was in
Hardy-Weinberg equilibrium (HWE).
SLC6A4 promoter methylation analysis
500 ng of genomic DNA was sodium bisulphite-converted
using the EZ-96 DNA Methylation-Lightning MagPrep kit
protocol (Zymo Research; Irvine, USA). The promoter-asso-
ciated CpG island was targeted in our assay. This region is
equivalent to amplicon 1 in a previous study [30]. A 335 bp
region (UCSC Human Genome Browser GRCh/hg_38
build: chr17: 30235734–30,236,068) [31] was amplified in
triplicate, to account for variation in the PCR step [32], and
methylation of 11 CpG units, encompassing 20 CpG sites,
were quantified using the SEQUENOM MassARRAY Epi-
TYPER platform (Additional file 1: Table S1) [32]. Raw
methylation data was generated on 361 samples. Mean
methylation values were calculated from replicates within
10% of the median value (Martino et al. 2013). Participants
with < 50% of methylation data available (n = 55) and out-
liers (> 3 times the interquartile range (IQR)) (n = 4) were
excluded from further analysis. Following these quality con-
trol steps (Additional file 1: Figure S1), methylation data
was obtained for a sub-sample of 302 participants, with no
significant difference in depression status, age, sex and key
variables (Table 1) with the full ESPRIT cohort (p > 0.05 for
all comparisons).
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Statistical analysis
Statistical analyses were performed using the statis-
tical software package Stata 14.1 (StataCorp, College
Station, Texas, USA). Univariate analysis (analysis of
variance, t-tests, χ2-tests) was performed to examine
potential associations between genotype and DNA
methylation, and between depression and DNA
methylation. Additionally, these statistical tests were
used to determine which population characteristics
were associated with depression status (Table 1)and/
or DNA methylation levels independently. This step
was performed to identify potential confounding fac-
tors of the association between DNA methylation and
depression, which thus would be considered further
in multivariate analysis. For associations between
population characteristics and methylation, the sig-
nificance threshold was set at a conservative level of
p < 0.15, to ensure that no potential confounding vari-
ables were omitted. Characteristics associated with
both depression and methylation were considered in
subsequent multivariate regression analysis as covari-
ates. This included age, sex, living alone, functional
impairment, ischemic disease, anxiety, comorbidities.
Multivariate linear regression models were used to
model the association between DNA methylation
(outcome variable) and depression (predictor variable),
while adjusting for the potential confounding factors.
Potential modifying effects of genetic variants on the
association between depression and DNA methylation
were also investigated through the inclusion of a
multiplicative interaction term in the multivariate
models. When potential modifying effects of a specific
genetic variant were found (at p < 0.15), stratified ana-
lysis of methylation data across the genotype groups
Table 1 Characteristics of study participants according to depression status
Characteristica No depression Depression p- valueg
n 207 95 –
Age (Mean ± S.D.) 72.5 ± 5.2 74.6 ± 5.7 0.004
Proportion (%)
Female 55.1 68.4 0.028
Past major depressive disorder 25.3 38.6 0.062
High education levelb 38.2 25.3 0.028
Living alone 20.9 43.2 < 0.001
Habitual alcohol drinkers (> 24 g/day) 19.2 20.4 0.81
Habitual smokers (≥10 pack years) 35.6 34.4 0.84
Functional impairmentc 5.31 13.7 0.013
Ischemic diseased 10.6 22.1 0.008
Comorbiditiese 12.1 29.5 < 0.001
Anxiety 15.9 29.5 0.044
Dementia 4.3 2.1 0.334
Impaired cognition (MMSE< 26)f 13.6 11.6 0.63
Antidepressants 3.38 12.6 0.002
Selective serotonin re-uptake inhibitor (SSRI) 2.90 6.3 0.158
Tricyclic antidepressant (TCA) 0.48 2.10 0.187
Other antidepressants 0.00 4.20 0.003
Benzodiazepines 4.83 9.47 0.123
Anxiolytics 7.73 16.8 0.017
Psychotropic drugs 4.83 11.6 0.032
Anticholinergics 4.83 7.37 0.374
aNot all participants with methylation data (n = 302) had information for each population characteristic listed, but missing data was < 2%, with exception of
anxiety (20.5%) and past MDD (33%)
bUnderwent post-secondary education of any type
cUnable to independently complete 2 items on both or either of the Instrumental Activities of Daily Living and Activities of Daily Living scales
dHistory of angina pectoris, myocardial infarction, stroke, cardiovascular surgery and/or arteritis
eHypertension (resting blood pressure ≥ 160/95 mmHg), high cholesterol (total cholesterol ≥6.2 mmol/l), diabetes (fasting glucose ≥7.0 mmol/l), thyroid disease,
asthma, or recent cancer diagnosed within the last 2 years
fMMSE: Mini-Mental State Examination
gChi-squared tests used to assess p-value for all variables except age, where a t-test was used
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was performed. This involved t-tests to determine the
association between depression status and DNA
methylation, in each genotype group of the specific
variant. Sensitivity analysis excluding antidepressant
users (n = 19) was performed as antidepressants may
potentially mask depression status and independently
influence methylation levels [33]. Sensitivity analysis
excluding participants with past depression (n = 59)
was also performed. Correction for multiple testing
was performed using the Benjamini-Hochberg false
discovery rate (FDR) method (FDR = 0.05).
Results
Study population
In this study of 302 participants, depressed individuals
(31.5%) were significantly more likely to be female, of older
age, have a lower education level, live alone, be functionally
impaired and have poorer health (ischemic pathologies and
comorbidities), as compared to non-depressed participants.
They were also more likely to be taking antidepressants.
Characteristics of participants according to depression are
shown in Table 1. All genotypes were in HWE (p > 0.05 for
all polymorphisms). Of the six genetic variants and one com-
bined variant examined, only 5-HTTLPR was significantly
associated with depression (Additional file 1: Table S2).
Association between promoter DNA methylation and
SLC6A4 genetic variants
Overall, the methylation levels at the 335 bp promoter
region were relatively low, apart from CpG 25.26 which
had the highest and most variable distribution of methyla-
tion (Fig. 1). Potential associations were observed between
specific genetic variants and DNA methylation, indepen-
dent of depression status (Table 2). In particular, homozy-
gous GG genotypes of rs140700 (p = 0.019) and rs25531
(p = 0.007) were significantly associated with higher
methylation at CpG 16–20, while homozygous CC geno-
types of rs25528 (p = 0.007) and rs6354 (p = 0.023) had
significantly higher methylation at CpG 21. However, it
should be noted that applying a FDR Benjamini-Hochberg
correction for multiple testing of 11 CpG units and 6
polymorphisms (FDR = 0.05) abolished these associations.
Association between depression and methylation
In unadjusted analysis, no significant differences in methy-
lation were noted between depressed and non-depressed
participants at any individual CpG units or the mean
methylation across the region (p > 0.15, except for CpG 3
with effect size Δ = 0.31%; 95% CI: 0.04; 0.67%, p = 0.084
comparing depressed with non-depressed individuals).
These findings did not change after inclusion of potential
confounders in regression models (as stated in methods),
or in sensitivity analysis excluding antidepressant users
(n = 19) or participants with past depression (n = 59).
Modification of the association between depression and
methylation by SLC6A4 genotype
Five SLC6A4 polymorphisms were found to potentially
modify the association between depression and DNA
methylation at multiple CpG units. 5-HTTLPR and
5-HTTLPR/rs25531 polymorphisms significantly modified
the depression-methylation associations at both CpG 21
(p-values for interaction term: 5-HTTLPR, p = 0.001;
5-HTTLPR/rs25531, p = 0.006) and CpG 25.26 (5-HTTLPR,
p = 0.064; 5-HTTLPR/rs25531, p = 0.030). In light of this,
analysis was stratified by genotype, where clear differences
in associations were observed.
Depression was significantly associated with lower
methylation levels at CpG 21 and CpG 25.26, but only for
individuals with the SS genotype of 5-HTTLPR (SS, Δ =−
1.60%; 95% CI: -2.54; − 0.65%; p = 0.001, Fig. 2a and Δ = −
4.31%; 95% CI: -7.14; − 1.48%; p = 0.004, Fig. 2c respect-
ively). In contrast, individuals with the LL genotype had
highermethylation at CpG 21 (LL, Δ = 0.88%; 95% CI: 0.10;
1.65%; p = 0.028, Fig. 2a). Similar genotype dependent asso-
ciations were likewise observed for 5-HTTLPR/rs25531 at
CpG 21 (S’S′, Δ = − 1.10%; 95% CI: -2.01; − 0.20; p = 0.018,
Fig. 2b) and CpG 25.26 (S’S′, Δ = − 4.39%; 95% CI: -6.95; −
1.84%; p = 0.001, Fig. 2d) and at CpG 21 for L’L’ genotype
(Δ = 1.18%; 95% CI: 0.21; 2.15; p = 0.019, Fig. 2b). These as-
sociations remained significant following multivariate ad-
justment for potential confounders, as shown in Table 3.
Following correction for multiple testing (FDR = 0.05), as-
sociations between depression and methylation at CpGs 21
(5-HTTLPR, SS) and 25.26 (5HTTLPR, SS; 5HTTLPR/
rs25531, S’S′) remained significant.
Fig. 1 Distribution of SLC6A4 methylation levels at each CpG unit
and mean methylation levels across the region studied for all study
participants. The box denotes the interquartile range (IQR: 25–75%
percentiles), the line shows the median and the whiskers are 1.5 x
IQR below the 25% percentile or above the 75% percentile
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Three other genotypes were also found to potentially
modify the associations between depression and methyla-
tion: rs140700 (mean methylation; p-values for interaction
term = 0.083), rs6354 (CpG 25.26; p = 0.061) and rs4251417
(CpG 27, p = 0.026). Following stratification; mean methyla-
tion was significantly lower in depressed patients with het-
erozygote rs140700 genotype (GA, Δ = − 1.17%; 95% CI:
-2.11; − 0.24%; p = 0.021; Additional file 1: Figure S2A);
CpG 25.26 had highermethylation in depression for hetero-
zygote rs6354 genotype (AC, Δ = 4.22%; 95% CI: 0.13;
8.32%; p = 0.044; Additional file 1: Figure S2B) and CpG 27
exhibited lowermethylation in depressed participants with
homozygote rs4251417 genotype (GG, Δ = − 0.40%; 95% CI:
-0.74; − 0.062%; p = 0.021; Additional file 1: Figure S2C).
However, none of these associations remained significant in
multivariate linear regression models (data not shown).
The overall relationships between SLC6A4 genetic var-
iants, promoter methylation and depression are shown
in Fig. 3.
Discussion
Our study investigated the relationship between SLC6A4
promoter methylation and six polymorphisms (5-HTTLPR,
rs140700, rs42151417, rs6354, rs25528, rs25531), plus a
combined variant (5-HTTLPR/rs25531) independently and
in the context of late-life depression. We found marginal
Table 2 Potential associations between SLC6A4 DNA methylation and genotype
CpG unit Genetic variant Average methylation (%) p-valuea
Major homozygote Heterozygote Minor homozygote
3 rs4251417 GG (3.04) GA (2.70) AA (1.56) 0.12
14.15 rs4251417 GG (2.26) GA (1.72) AA (1.67) 0.095
16.17.18.19.20 rs140700 GG (7.14) GA (5.73) AA (4.92) 0.019
rs6354 AA (7.29) AC (6.43) CC (6.03) 0.054
rs25531 AA (7.06) AG (5.74) GG (8.44) 0.007
21 rs25528 AA (3.54) AC (4.55) CC (4.94) 0.007
rs4251417 GG (4.03) GA (3.17) AA (3.06) 0.085
rs6354 AA (3.53) AC (4.30) CC (4.94) 0.023
5-HTTLPR LL (3.85) SL (4.03) SS (4.55) 0.077
ap-values calculated by one-way ANOVAs and only those with p < 0.15 shown
Fig. 2 DNA methylation at CpG units 21 and 25.26 according to depression status, stratified by serotonin transporter (SLC6A4) genotypes: 5-
HTTLPR and 5-HTTLPR/rs25531. a CpG 21, 5-HTTLPR (n = 274); (b) CpG 21, 5-HTTLPR/rs25531 (n = 210); (c) CpG 25.26, 5-HTTLPR (n = 234); (d) CpG
25.26, 5-HTTLPR/rs25531 (n = 182). Data presented as mean methylation ±95% CI. T-tests were used to calculate p-values, with significant
associations at p < 0.05 indicated in the figure
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and nominally significant evidence that six genetic variants
influenced site-specific methylation at four out of 11 CpG
units. Whilst methylation was not independently associated
with depression, specific genotypes were found to modify
the association between depression and methylation at sev-
eral CpG units. In particular, for individuals with the SS or
S’S genotypes of 5-HTTLPR and 5-HTTLPR/rs25531 re-
spectively, depression was significantly associated with low-
ermethylation at CpG 21 and CpG 25.26. On the other
hand, for individuals carrying the LL or L’L’ genotypes, de-
pression was nominally associated with higher methylation
at CpG 21. These findings were not confounded by sex,
age, antidepressant use, or other factors examined including
living situation and comorbidities.
Differential SLC6A4 methylation at the promoter CpG
island has been correlated with risk factors and adversities
related to depression. Associations has been observed
between maternal depression and decreased infant SLC6A4
promoter methylation [34]. In adults, increased methylation
has been associated with childhood trauma [35] and stress
(early life and recent) [30, 36]. An inverse correlation be-
tween SLC6A4 mRNA levels and promoter methylation has
been demonstrated [11]. Several studies support our find-
ings, reporting no association between SLC6A4 methylation
in blood and depression in adults, in either Caucasian [12]
or three Asian (n = 108; n = 286; n = 100) [14, 15, 17] popu-
lations, as well as in buccal mucosa from Caucasian adoles-
cents (n = 150) [16] and EBV-transformed lymphoblasts (n
= 192) [18]. In contrast, three studies found positive associ-
ations between peripheral SLC6A4 methylation in blood
and depression in Caucasian (n = 57) [13] and Asian adults
(n = 151; n = 84) [19, 20], two of which had overlapping
assay regions with our study [19, 20]. Interestingly, Shi et al.
(2016) found significantly highermethylation at two CpG
Table 3 Adjusted associations between depression and SLC6A4 promoter methylation, stratified by 5-HTTLPR or 5-HTTLPR/rs25531
genotype
CpG unit Genotype Variables Unadjusted Adjusteda
β(SE) p-value β(SE) p-value
21 5-HTTLPR (LL) Depression 0.24 (0.39) 0.026 0.28 (0.41) 0.016
Female sex − 0.092 (0.39) 0.39
Age (yrs) 0.024 (0.036) 0.83
Antidepressants −0.15 (0.83) 0.18
5-HTTLPR (SS) Depression −0.38 (0.52) 0.004 −0.44 (0.54) 0.001
Female sex −0.17 (0.58) 0.22
Age (yrs) −0.03 (0.068) 0.82
Antidepressant 0.13 (0.96) 0.33
Living alone 0.38 (0.69) 0.018
5-HTTLPR/rs25531 (L’L) Depression 0.33 (0.49) 0.019 0.36 (0.53) 0.019
Female sex 0.074 (0.48) 0.60
Age (yrs) −0.005 (0.057) 0.97
Antidepressant −0.093 (1.3) 0.54
5-HTTLPR/rs25531 (S’S′) Depression −0.28 (0.49) 0.027 −0.30 (0.50) 0.023
Female sex −0.14 (0.49) 0.29
Age (yrs) −0.22 (0.59) 0.097
Antidepressant 0.098 (0.87) 0.44
Living alone 0.27 (0.60) 0.056
25.26 5-HTTLPR (SS) Depression −0.37 (1.58) 0.009 −0.31 (1.68) 0.038
Sex −0.26 (1.65) 0.068
Age (yrs) −0.076 (0.20) 0.60
Antidepressant −0.087 (3.06) 0.56
5-HTTLPR/rs25531 (S’S′) Depression −0.37 (1.53) 0.006 −0.31 (1.52) 0.020
Sex −0.19 (1.46) 0.13
Age (yrs) −0.26 (0.18) 0.046
Antidepressant −0.11 (2.71) 0.39
aAdjusted for age, sex and antidepressant use, plus confounding factors (see methods) which remained significant in the final models at p < 0.15
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sites (Δ = 2.52 and 0.15) corresponding to CpG 25.26 in our
study, which we failed to find, despite this unit having the
highest level and variability of methylation.
It is increasingly clear that genetic variation plays a crit-
ical role in the regulation of DNA methylation [21]. Such
loci, referred to as methylation quantitative trait loci
(mQTLs), may also modify the association between DNA
methylation risk of disease [37, 38]. Previous studies that
have investigated the extent to which SLC6A4 genotype
can influence DNA methylation in the context of depres-
sion, have focused primarily on the 5-HTTLPR poly-
morphism. Several reported no significant association
with mean methylation [12, 16, 17], which is supported by
our findings. However, we did observe a trend for an asso-
ciation between 5-HTTLPR SS genotype and higherCpG
21 methylation (p = 0.077), which is in concordance with a
study in post-stroke depression [15]. In addition, rs25531,
which has been shown to modify the functionality of
5-HTTLPR [27, 29] was also associated with site-specific
methylation at CpG unit 16–20. Here we have shown for
the first time that four other polymorphisms (rs4251417,
rs140700, rs6354 and rs25528) in SLC6A4 may potentially
regulate DNA methylation in the region.
Modifying effects of 5-HTTLPR genotype on the
association between SLC6A4 methylation and several
depression-related adversities, including childhood abuse
[12] and stress [36], have been demonstrated previously.
The few studies which have investigated this in the con-
text of depression, have found that the S allele in combin-
ation with higherSLC6A4 methylation increased the risk
of depressive symptoms in adolescents [16] and adults
following stroke [15]. This contrasts with our current
study which observed lower methylation at CpG units 21
and 25.26 in depressed older individuals with the SS geno-
type. However, a recent study by Iga et al. (2016) (average
age: 42.2–45.0 years) found that the L allele was associ-
ated with higherperipheral blood methylation in de-
pressed patients [13]. More broadly, as an inverse
correlation exists between SLC6A4 methylation and
mRNA levels [11], our finding of decreased methyla-
tion in depressed individuals is consistent with the ob-
servation of increased peripheral SLC6A4 mRNA in
un-medicated MDD patients [39–41].
The vast majority of epigenetic studies of 5-HTTLPR did
not consider SL genotype individually, which makes it hard
to determine the real (in)consistency of data [8]. Similar to
Iga et al., we found highermethylation at CpG 21 in de-
pressed older individuals with the LL genotype, although
this was only nominally significant in our study. Interest-
ingly, previous findings also indicate that age can influence
the association between 5-HTTLPR and mental health [8].
Given the larger sample size, our findings further
strengthen the evidence that 5-HTTLPR plays a role in
modifying the association of methylation with depres-
sion. We also found significant modifying effects from
the triallelic 5-HTTLPR/rs25531 polymorphism. Whilst
5-HTTLPR/rs25531 modification effects have not been
studied in relation to the CpG island, a recent study
found that carriers of the S′ allele had lowermethylation
at a neighboring Alu retrotransposon (AluJb) in associ-
ation with stress [42], which is in a similar direction of
effect found in our study.
Fig. 3 Diagram of relationships between SLC6A4 genetic variants, promoter methylation and depression. Solid lines indicate an association. The X
denotes the interaction between genetic variants and SLC6A4 methylation in association with depression (dot-dash line). Bolded genetic variants
or DNA methylation sites in boxes were independently associated, but also interacted to influence depression risk. Interactions which remained
significant following FDR correction are boxed
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This is also the first study to examine the potential
modifying effects of other polymorphisms throughout the
SLC6A4 gene on the depression-methylation association.
Here, we report modifying effects from rs140700,
rs4251417, rs6354, but these associations did not remain
significant following multivariate adjustment. This may be
because of the relatively small sample size with these ge-
notypes, in particular because there were too few minor
homozygotes to include in the analysis, with the compari-
son instead been only between major homozygotes and
heterozygotes. Therefore, a larger sample size able to cap-
ture the minor homozygote is needed to further investi-
gate these associations. Overall, the effects of genotype
and methylation may combine to exert another layer of
regulation in modifying risk of depression. Further investi-
gation is needed to examine the underlying mechanisms
and its function in influencing depression risk.
Our study of 302 participants is larger than all previous
studies investigating SLC6A4 methylation and genetic vari-
ation in depression. However only subtle differences in
DNA methylation levels have been observed in peripheral
tissues in association with psychiatric disorders, suggesting
that an even larger sample size may be required to fully re-
veal true associations. We were able to consider several
polymorphisms throughout the gene in combination with
promoter methylation in our study, and adjust for a wide
variety of confounding factors including sex, age and anti-
depressant use. Our participants were from the general
population, thus making our findings more generalisable, as
opposed to studies focused only on depressed hospital pa-
tients. Late-life depression covers a range of mild to severe
depressive symptoms [43], so the CES-D scale to assess de-
pressive symptoms, together with the DSM-IV classification
of MDD (American Psychiatric Association, 1994), has
helped ensure non-depressed individuals in this study did
not have significant levels of sub-clinical symptomatology.
Whilst our results may be generalisable to the older popula-
tion, it may not be the case for earlier onset depression and
non-Caucasian populations. Contributors to the etiology of
depression may vary by age of onset, with late-life depres-
sion more frequently comorbid with physical and psychi-
atric conditions such as cardiovascular disease and stroke
[44]. Depressive symptoms are also more frequent amongst
the oldest old, which may be explained by factors associated
with aging, such as higher proportion of women and in-
creased physical impairment [44]. This is consistent with
our finding that depressed individuals are significantly more
likely to be female, older and functionally impaired (Table
1). DNA methylation patterns have been reported to vary
with age, sex and ethnicity [45, 46]. Specifically, global hy-
pomethylation has been reported in females [46] and with
increasing age [45]. Hence, decreases in SLC6A4 methyla-
tion, as observed in this study, may be specifically associ-
ated with late-life depression.
Other limitations to our study are the cellular hetero-
geneity of blood, the cross-sectional design of this study
and potential residual confounding from factors for which
information was not available or collected. Our study fo-
cused on white blood cells, which contain a heterogenous
assortment of cell types. Given the cell-type-specific na-
ture of methylation, variation in cellular composition may
lead to distinct methylation profiles between cell types,
potentially confounding methylation-related analyses [47].
This may account for the lack of associations observed be-
tween depression and SLC6A4 methylation in our study.
Cellular heterogeneity cannot be controlled for in a candi-
date gene study such as ours. Epigenome-wide association
studies, on the other hand, have the ability to computa-
tionally adjust for cellular heterogeneity [48], with the
added advantage of being able to interrogate large propor-
tions of the (epi)genome without an a priori hypothesis.
Finally, as an association study, we are unable to draw
any conclusions about the functionality or causality of our
findings. Using peripheral methylation to examine a brain-
based disorder has its limitations, as methylation profiles
can also be distinct across different tissues. A few studies
have reported correlations between DNA methylation levels
in blood and post-mortem brain tissue, although these are
likely to be gene-specific [49, 50]. Changes in peripheral tis-
sues, such as in inflammatory markers, have been observed
in depression, therefore becoming increasingly recognised
as a systemic disease [51, 52]. Further, both SLC6A4 methy-
lation and genetic variants have been correlated with brain
structural changes, including the hippocampus and corpus
callosum, in depressed individuals [12, 53–55]. As such,
our study may provide support for SLC6A4 methylation as
a biomarker of depression, indicating that such a biomarker
would need to consider SLC6A4 methylation in combin-
ation with genetic variation.
Conclusion
Our study of late-life depression did not find any strong
evidence for an independent association between SLC6A4
promoter methylation and depression, however this may
be modified by underlying genetic variants in the region.
Further investigation is needed to examine the mecha-
nisms behind such interactions, and replication in larger,
independent and longitudinal studies are needed to help
confirm these findings.
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